|drug3048||Povidone-Iodine 2% Wiki||1.00|
|drug2024||Isotonic saline 0.9% Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."
Description: Nasopharyngeal swabs will be obtained and quantitative polymerase chain reaction (PCR) testing will be performed to determine the viral load in the nasopharynxMeasure: Mean change in viral titers of SARS-CoV-2 Time: Day 1 (baseline), Day 1 (1 hour), Day 3
Description: Adverse effects of interest include: Nasal burning/pain Headaches Ear pain Sneezing Nose bleedsMeasure: Frequency of adverse effects of interest after nasal sprays Time: Up to 5 days
Description: Symptoms of interest include: Fever Fatigue Change in smell Change in taste Nasal obstruction Chills Sore throatMeasure: Frequency of symptoms related to SARS-CoV-2 Time: Up to 5 days
Description: Self report by participants (survey) of estimated doses completed.Measure: Compliance with study drug administration Time: Up to 5 days
Description: Participants scratch the cards and attempt to identify the smell from a multiple choice set of options. Their scores are then computed and categorized as normal, mild, moderate, or severe microsmia (loss of smell).Measure: Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT) Time: Day 1 (baseline), Day 30
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports